NCT03571321 Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Status RECRUITING Phase PHASE1
NCT03558607 The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm Status UNKNOWN Phase PHASE1/PHASE2
NCT03515200 Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia Status TERMINATED Phase PHASE1
NCT03514069 Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03491215 Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease Status COMPLETED Phase PHASE1/PHASE2
NCT03427866 Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. Status COMPLETED Phase PHASE2
NCT03386214 Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis Status TERMINATED Phase PHASE1
NCT03373877 Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis Status TERMINATED Phase PHASE1
NCT03286530 Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03222609 A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis Status COMPLETED Phase PHASE2
NCT03147742 An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant Status APPROVED_FOR_MARKETING Phase N/A
NCT03144687 A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis Status COMPLETED Phase PHASE2
NCT03123588 Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) Status TERMINATED Phase PHASE2
NCT03117751 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2/PHASE3
NCT03112603 A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Status COMPLETED Phase PHASE3
NCT03069326 A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03041636 Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Status COMPLETED Phase PHASE2
NCT03017820 A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Status RECRUITING Phase PHASE1
NCT02974647 Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma Status RECRUITING Phase PHASE2